On October 13, WUXI BIO fell 3.7% in regular trading, trading at HK$51.0/share, with Turnover of HK$1.35 billion.

The decline was driven by continued weakness across Hong Kong's biopharmaceutical sector, as the CXO complex faced pressure with short-term profit-taking persisting. The Hang Seng Biotech Index had fallen 3.15% on October 7 and a further 2.31% on October 9, weighing on sector sentiment and directly impacting WUXI BIO. Despite the company's mid-year results showing revenue of RMB 11.787 billion, adjusted net profit of RMB 3.937 billion, and gross margin improving to 46.2%, the prior sector-wide recovery prompted some investors to lock in gains, intensifying the correction pressure.

WUXI BIO is an investment holding company primarily providing end-to-end solutions and services for biologics discovery, development, and manufacturing to clients in the biologics industry. The company operates through its Biologics segment and its WuXi XDC segment, which offers CRDMO services for antibody-drug conjugates and various bioconjugates, serving both domestic and international markets.